Glucagon Market Size & Growth Forecast 2027–2036, By Segments (Product Type, Distribution Channel, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Glucagon Market size was assessed at USD 476.76 Million in 2026 and is poised to grow at 6.89% CAGR between 2027 and 2036, reaching USD 928.26 Million by 2036. The industry revenue for 2027 is calculated at USD 504.65 Million.
Get more details on this report
Request Free Sample ReportGlucagon Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to well-developed healthcare infrastructure, high awareness of severe hypoglycemia, and strong access to emergency diabetes management therapies.
- Asia Pacific is expected to grow fastest as diabetes burden, healthcare accessibility, modern diabetes treatments, and awareness of hypoglycemia management increase.
Segment Momentum
- Hypoglycemia leads the market because glucagon is a critical emergency treatment for severe low blood glucose, with increasing awareness and wider access to rescue therapies supporting sustained demand.
- The gastrointestinal disorders segment is expanding as glucagon is increasingly used during diagnostic imaging and endoscopic procedures to temporarily relax gastrointestinal smooth muscle and improve procedural outcomes.
Market Expansion Drivers
- Rising global diabetes prevalence increasing demand for emergency glucagon therapies
- Advancements in drug delivery systems improving usability and adoption of glucagon products
- Increased R&D investment accelerating innovation in next-generation metabolic disorder treatments
Leading Market Participants
- Prominent companies in the glucagon market include Eli Lilly and Company (United States), Novo Nordisk A/S (Denmark), Xeris Biopharma Holdings (United States), Zealand Pharma A/S (Denmark), Fresenius Kabi (Germany), Amphastar Pharmaceuticals (United States), Hanmi Pharmaceutical Co., Ltd. (South Korea), Lupin Limited (India), Sanofi (France), Sandoz Group AG (Switzerland)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 476.76 Million
- 2027 Estimated Market Size: USD 504.65 Million
- Projected Market Size: USD 928.26 Million by 2036
- Growth Forecast: 6.89% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Injectable (Product Type) | Hospital Pharmacies (Distribution Channel) | Hypoglycemia (Application)
- Emerging Opportunity Segment: Inhalation (Product Type) | Online Pharmacies (Distribution Channel) | Gastrointestinal Disorders (Application)
Market Growth Drivers and Industry Trends
Rising global diabetes prevalence increasing demand for emergency glucagon therapies
The growing incidence of diabetes across both developed and emerging economies is creating sustained demand for rapid-response treatments that address severe hypoglycemic events. The glucagon market will drive growth as healthcare providers, caregivers, and patients increasingly prioritize emergency preparedness for individuals using intensive insulin therapy. Rising awareness of hypoglycemia risks has encouraged broader prescribing practices, while clinical guidelines emphasizing timely intervention have supported the inclusion of glucagon products in diabetes management plans. Expanding access to diabetes care services, improved diagnosis rates, and greater education on recognizing hypoglycemic emergencies are also encouraging wider availability of emergency glucagon therapies across hospitals, pharmacies, and home-care settings.
Advancements in drug delivery systems improving usability and adoption of glucagon products
Innovations in administration technologies are removing many of the practical barriers that historically limited emergency glucagon use during critical situations. By simplifying preparation and reducing the complexity associated with traditional formulations, the glucagon market is benefiting from greater acceptance among caregivers, family members, educators, and first responders who may have limited medical training. User-friendly delivery formats improve confidence in emergency administration, reduce the likelihood of dosing errors, and enhance treatment accessibility outside clinical environments. These improvements also encourage healthcare professionals to recommend glucagon products more routinely as part of comprehensive diabetes emergency preparedness strategies.
Increased R&D investment accelerating innovation in next-generation metabolic disorder treatments
Expanding research activity in metabolic diseases is broadening scientific understanding of glucagon biology and creating opportunities for the development of more advanced therapeutic approaches. Increased investment from pharmaceutical developers and research institutions will propel the glucagon market growth by supporting the discovery of improved formulations, combination therapies, and novel treatment concepts that address unmet clinical needs. Continuous innovation is also strengthening development pipelines focused on improving product stability, therapeutic effectiveness, and patient convenience while expanding the potential applications of glucagon-based therapies across a wider range of metabolic conditions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global diabetes prevalence increasing demand for emergency glucagon therapies | 2.5% | High | North America, Europe | High | Near Term |
| Advancements in drug delivery systems improving usability and adoption of glucagon products | 2.2% | High | Europe, Asia Pacific | Medium | Mid Term |
| Increased R&D investment accelerating innovation in next-generation metabolic disorder treatments | 2.1% | High | North America, Europe | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the glucagon market in 2026, owing to well-developed healthcare infrastructure, high awareness of severe hypoglycemia, and greater access to emergency diabetes management therapies. The region's established healthcare systems support the diagnosis and treatment of diabetes and facilitate the adoption of glucagon products for emergency use. Increasing emphasis on patient safety and preparedness for hypoglycemic episodes also contributes to sustained demand for readily accessible glucagon therapies.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to be the fastest-growing region over the forecast period, supported by the rising burden of diabetes, improving healthcare accessibility, and growing awareness of hypoglycemia management. Expanding healthcare infrastructure and increasing availability of modern diabetes treatments are enabling more patients to receive appropriate emergency care. Greater awareness among patients, caregivers, and healthcare professionals regarding the importance of timely treatment for severe hypoglycemia is also expected to strengthen the adoption of glucagon products across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Diabetes Emergency AccessThe U.S. glucagon market emphasizes rapid treatment of severe hypoglycemia through expanded availability of user-friendly rescue products. Healthcare providers and payers increasingly support formulations that simplify emergency administration for patients and caregivers.
Germany 🇩🇪
Clinical Treatment StandardsGermany integrates glucagon products within structured diabetes management and emergency care protocols. Healthcare stakeholders prioritize reliable formulations, patient education, and treatment options that support timely intervention during hypoglycemic events.
Japan 🇯🇵
Patient-Centered InnovationJapan encourages adoption of convenient glucagon formulations that improve emergency preparedness for individuals with diabetes. Healthcare providers increasingly focus on ease of administration and better support for home-based diabetes management.
South Korea 🇰🇷
Modern Diabetes CareSouth Korea advances glucagon utilization through expanding diabetes care services and greater awareness of severe hypoglycemia management. Healthcare organizations prioritize accessible rescue therapies supported by patient and caregiver education initiatives.
France 🇫🇷
Integrated Diabetes SupportFrance incorporates glucagon therapies into comprehensive diabetes management programs that emphasize timely emergency intervention. Clinical priorities include practical administration methods and broader patient access through coordinated healthcare services.
Italy 🇮🇹
Community Care ReadinessItaly promotes glucagon availability across hospitals, community healthcare, and outpatient diabetes services to strengthen emergency preparedness. Healthcare professionals increasingly encourage caregiver training and practical treatment approaches that improve response during hypoglycemic emergencies.
Glucagon Market Share (%), by Product Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Type Segment Analysis: Injectable (Largest Segment) vs Inhalation (Fastest-Growing Segment)
The injectable segment held the largest share of the glucagon market in 2026. Injectable glucagon has long been established as the standard emergency treatment for severe hypoglycemia due to its proven clinical effectiveness and widespread availability across healthcare settings. Strong physician familiarity, well-defined treatment protocols, and broad integration into emergency care practices have reinforced the segment's leading position.
The inhalation segment is expected to experience the fastest growth as demand increases for non-invasive treatment options that improve patient convenience and simplify administration. Needle-free delivery methods can enhance user acceptance while reducing barriers associated with injectable therapies. Continued innovation in drug delivery technologies and growing emphasis on improving emergency treatment accessibility are expected to support rapid expansion of this segment.
Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)
The glucagon market was led by the hospital pharmacies segment in 2026. Hospital pharmacies play a critical role in ensuring immediate availability of glucagon for emergency management of severe hypoglycemia and other clinical applications. Their integration with inpatient and emergency care services, along with established procurement systems and clinical oversight, has supported the segment's market leadership.
The online pharmacies segment is projected to witness the fastest growth due to increasing consumer preference for convenient medicine purchasing and home delivery services. Expanding digital healthcare platforms, improved accessibility to prescription medications, and greater adoption of telehealth services are encouraging more patients to obtain glucagon through online distribution channels. These trends are expected to strengthen the segment's growth over time.
Application Segment Analysis: Hypoglycemia (Largest Segment) vs Gastrointestinal Disorders (Fastest-Growing Segment)
The hypoglycemia segment represented the largest application in the glucagon market in 2026. Glucagon remains a critical therapy for the emergency treatment of severe hypoglycemia, particularly among individuals with diabetes who require rapid restoration of blood glucose levels. Increasing awareness of emergency preparedness and broader access to glucagon rescue therapies have continued to support the segment's dominant position.
The gastrointestinal disorders segment is expected to record the fastest growth as glucagon gains wider use in diagnostic and procedural settings requiring temporary relaxation of gastrointestinal smooth muscle. Growing utilization of advanced diagnostic imaging and endoscopic procedures, together with increased emphasis on improving procedural accuracy and patient outcomes, is contributing to the expanding adoption of glucagon in gastrointestinal applications.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product Type | Injectable, Inhalation | Injectable | Inhalation |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | Hospital Pharmacies | Online Pharmacies |
| Application | Hypoglycemia, Diagnostic Aid, Gastrointestinal Disorders, Cardiogenic Shock, Others | Hypoglycemia | Gastrointestinal Disorders |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Key companies in the glucagon market:
- Eli Lilly and Company (United States)
- Novo Nordisk A/S (Denmark)
- Xeris Biopharma Holdings (United States)
- Zealand Pharma A/S (Denmark)
- Fresenius Kabi (Germany)
- Amphastar Pharmaceuticals (United States)
- Hanmi Pharmaceutical Co., Ltd. (South Korea)
- Lupin Limited (India)
- Sanofi (France)
- Sandoz Group AG (Switzerland)
The glucagon market is moving toward a more differentiated competitive environment as suppliers focus on improving therapeutic accessibility, delivery convenience, and integration with evolving diabetes management approaches. Manufacturers are strengthening their positions through advancements in formulation strategies and patient-oriented delivery options, while specialized entrants are targeting unmet needs through more focused therapeutic developments. Competitive dynamics are increasingly shaped by the ability to enhance treatment experience, support broader clinical adoption, and align solutions with changing expectations among healthcare providers and patients.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company (United States) | |||||||
| Novo Nordisk A/S (Denmark) | |||||||
| Xeris Biopharma Holdings (United States) | |||||||
| Zealand Pharma A/S (Denmark) | |||||||
| Fresenius Kabi (Germany) | |||||||
| Amphastar Pharmaceuticals (United States) | |||||||
| Hanmi Pharmaceutical Co. Ltd. (South Korea) | |||||||
| Lupin Limited (India) | |||||||
| Sanofi (France) | |||||||
| Sandoz Group AG (Switzerland) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Eli Lilly | May-26 | Eli Lilly expanded its manufacturing footprint in Indiana with an additional $4.5 billion investment. This capital injection is dedicated to scaling production capacity for tirzepatide, oral GLP-1 therapies, and genetic medicines, substantially reinforcing its competitive infrastructure to satisfy surging global demand for incretin-based therapeutics. |
| Boehringer Ingelheim | Apr-26 | Boehringer Ingelheim disclosed positive Phase 3 SYNCHRONIZE-1 clinical data for survodutide, its dual glucagon/GLP-1 receptor agonist. The candidate demonstrated significant weight reduction over a 76-week period, validating its therapeutic efficacy and advancing the company's competitive positioning in the next-generation obesity market. |
| Eli Lilly | Feb-26 | Eli Lilly expanded its long-term strategic collaboration with Innovent Biologics via a seventh R&D agreement valued at over $8.8 billion, including a $350 million upfront payment. This major financial commitment solidifies their joint development capabilities focused on advanced therapeutics for metabolic diseases. |
| Lupin Limited | Aug-25 | Lupin Limited launched its generic Glucagon for Injection USP (1 mg/vial) emergency kit in the United States. Bioequivalent to Eli Lilly's reference product, this launch expands Lupin's critical diabetes-care injectables portfolio and introduces a competitive alternative for treating severe hypoglycemia. |
| Innovent Biologics | Jun-25 | Innovent Biologics obtained a landmark first-in-class regulatory approval in China for mazdutide, a dual GLP-1/glucagon receptor agonist developed in partnership with Eli Lilly. The regulatory milestone marks a significant commercial entry into the regional obesity treatment market with a highly differentiated therapeutic mechanism. |
| Novo Nordisk | Mar-25 | Novo Nordisk secured a licensing agreement valued at up to $2 billion to acquire the rights for UBT251, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. The acquisition strategically expands the company's clinical pipeline of next-generation obesity and metabolic disease treatments. |
| OPKO Health | Mar-25 | OPKO Health formalized a strategic partnership with Entera Bio to advance the first oral dual GLP-1/glucagon receptor agonist into clinical development. The collaboration leverages specialized oral peptide platform technology to create differentiated, non-injectable treatment alternatives for the metabolic and obesity sectors. |
| Xeris Pharmaceuticals | May-24 | Xeris Pharmaceuticals established an exclusive global collaboration with Beta Bionics to develop a dedicated glucagon product optimized for proprietary insulin pump technologies. This initiative drives commercial innovation in automated diabetes management by integrating specialized glucagon formulations directly into automated dual-hormone delivery systems. |
| WuXi STA | Apr-24 | WuXi STA initiated a multi-site global facility expansion to significantly increase its peptide manufacturing capacity alongside advanced API and drug product infrastructure. This operational investment enhances global supply chain resilience and contract development capabilities to support the accelerating volume of peptide-based therapeutics. |
| Novo Holdings | Feb-24 | Novo Holdings agreed to acquire Catalent for $16.5 billion in a strategic transaction designed to expand manufacturing capacity. The acquisition directly supports production scaling for Novo Nordisk's expanding portfolio of GLP-1 and obesity therapeutics, addressing global supply constraints within the high-growth metabolic disease market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Glucagon Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Age Group | Pediatric, Adult, Geriatric |
| Treatment Setting | Hospitals & Emergency Care, Ambulatory & Outpatient Care, Home & Self-Administration |
| Reimbursement Status | Reimbursed, Partially Reimbursed, Self-Pay & Non-Reimbursed |
Glucagon Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Diabetes Care Pathway Assessment |
|
| Reimbursement and Market Access Strategy |
|
| Pipeline Commercial Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the current revenue of the glucagon market?
How is the glucagon industry size expected to evolve during the forecast period?
How are advancements in drug delivery improving glucagon adoption?
Why is increased R&D investment important for the future of the glucagon market?
Why is hypoglycemia the largest application segment in the glucagon market?
Why are gastrointestinal disorders the fastest-growing application segment?
Why does North America lead the glucagon market?
How is Asia Pacific driving future glucagon market growth?
Which companies are driving growth in the glucagon landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook